Oncostatin M is a differentiation factor for myeloid leukemia cells

• Published in: The Journal of immunology (1950) Vol. 149; no. 4; pp. 1271 - 1275
• Main Authors: Bruce, AG, Hoggatt, IH, Rose, TM
• Format: Journal Article
• Language: English
• Published: Bethesda, MD Am Assoc Immnol 15.08.1992; American Association of Immunologists
• Subjects: Analysis of the immune response. Humoral and cellular immunity; Animals; Biological and medical sciences; Cell Differentiation; Cell Division - drug effects; Colony-Forming Units Assay; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Granulocyte Colony-Stimulating Factor - pharmacology; Growth Inhibitors - pharmacology; Humans; Immunobiology; In Vitro Techniques; Interleukin-6 - pharmacology; Leukemia Inhibitory Factor; Leukemia Inhibitory Factor Receptor alpha Subunit; Leukemia, Myeloid - pathology; Lymphokines - pharmacology; Macrophages - cytology; Melanoma - metabolism; Melanoma - pathology; Mice; Miscellaneous; Oncostatin M; Peptides - pharmacology; Receptors, Cytokine; Receptors, Immunologic - physiology; Receptors, OSM-LIF; Regulatory factors and their cellular receptors; Tumor Cells, Cultured; Human; Granulocyte; Rodentia; Cytokine; Glycoproteins; Malignant hemopathy; Cell differentiation; Biological activity; Interleukin 6; Vertebrata; Granulocyte colony stimulating factor; Mammalia; Mouse; Comparative study; Acute myelocytic leukemia
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.149.4.1271

Oncostatin M (OSM) is a 28-kDa glycoprotein produced by stimulated macrophages and T lymphocytes that inhibits the proliferation of a number of different cell lines derived from solid tumors. Analysis of both amino acid sequence and gene structure has demonstrated that OSM is a member of a cytokine family that includes leukemia inhibitory factor (LIF), IL-6, and granulocyte colony-stimulating factor (G-CSF). We demonstrate that, like LIF, IL-6 and G-CSF, OSM can induce the differentiation of the myeloblastic M1 murine leukemia cells into macrophage-like cells. The morphologic and functional changes induced by OSM are more similar to those observed with LIF and IL-6 than those induced with G-CSF. OSM can also induce the differentiation of the histiocytic U937 human leukemia cells in the presence of granulocyte-macrophage CSF, a property shared with LIF and IL-6. In murine M1 cells, binding of labeled OSM is completely inhibited by excess LIF or OSM, reflecting the binding of OSM to the high affinity form of the murine LIF receptor. In contrast, the binding of labeled OSM to human U937 leukemia cells is inhibited by OSM, but the inhibition by LIF is significantly less. These results suggest that, in human leukemia cells, OSM may act through the LIF receptor and an OSM-specific receptor. The existence of an OSM-specific receptor was confirmed by both growth inhibition and competition binding assays on A375 human melanoma cells. The growth of human A375 cells was inhibited by OSM and IL-6 but not LIF or G-CSF. Neither LIF, G-CSF, nor IL-6 could compete with the binding of labeled OSM to A375 cells.